DE602005022052D1 - Nukleinsäurekonstrukt mit vollängengenom des menschlichen hepatitis-c-virus, rekombinantes vollängen-virusgenom replizierende zelle mit dem in sie übertragenen nukleinsäurekonstrukt und verfahren zur konstruktion von hepatitis-c-viruspartikeln - Google Patents
Nukleinsäurekonstrukt mit vollängengenom des menschlichen hepatitis-c-virus, rekombinantes vollängen-virusgenom replizierende zelle mit dem in sie übertragenen nukleinsäurekonstrukt und verfahren zur konstruktion von hepatitis-c-viruspartikelnInfo
- Publication number
- DE602005022052D1 DE602005022052D1 DE602005022052T DE602005022052T DE602005022052D1 DE 602005022052 D1 DE602005022052 D1 DE 602005022052D1 DE 602005022052 T DE602005022052 T DE 602005022052T DE 602005022052 T DE602005022052 T DE 602005022052T DE 602005022052 D1 DE602005022052 D1 DE 602005022052D1
- Authority
- DE
- Germany
- Prior art keywords
- virus
- nucleic acid
- hepatitis
- full
- constructure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000711549 Hepacivirus C Species 0.000 title 2
- 108020004707 nucleic acids Proteins 0.000 title 2
- 150000007523 nucleic acids Chemical class 0.000 title 2
- 102000039446 nucleic acids Human genes 0.000 title 2
- 241000282414 Homo sapiens Species 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000003362 replicative effect Effects 0.000 title 1
- 230000004044 response Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24241—Use of virus, viral particle or viral elements as a vector
- C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004045489 | 2004-02-20 | ||
PCT/JP2005/003232 WO2005080575A1 (ja) | 2004-02-20 | 2005-02-21 | ヒトc型肝炎ウイルスの全長ゲノムを含む核酸構築物及び該核酸構築物を導入した組換え全長ウイルスゲノム複製細胞、並びにc型肝炎ウイルス粒子の作製方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005022052D1 true DE602005022052D1 (de) | 2010-08-12 |
Family
ID=34879394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005022052T Active DE602005022052D1 (de) | 2004-02-20 | 2005-02-21 | Nukleinsäurekonstrukt mit vollängengenom des menschlichen hepatitis-c-virus, rekombinantes vollängen-virusgenom replizierende zelle mit dem in sie übertragenen nukleinsäurekonstrukt und verfahren zur konstruktion von hepatitis-c-viruspartikeln |
Country Status (9)
Country | Link |
---|---|
US (2) | US7659103B2 (de) |
EP (2) | EP1942191B1 (de) |
JP (1) | JP4921164B2 (de) |
KR (1) | KR101154278B1 (de) |
CN (2) | CN1942585B (de) |
CA (2) | CA2851807C (de) |
DE (1) | DE602005022052D1 (de) |
ES (2) | ES2366303T3 (de) |
WO (1) | WO2005080575A1 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4573776B2 (ja) * | 2003-09-19 | 2010-11-04 | 財団法人 東京都医学研究機構 | 新規hcv株由来の核酸、遺伝子、及び該遺伝子を利用したレプリコン複製細胞 |
CA2851807C (en) * | 2004-02-20 | 2016-06-28 | Toray Industries, Inc. | Nucleic acid construct containing full length genome of human hepatitis c virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis c virus particle |
JP5086082B2 (ja) * | 2004-10-01 | 2012-11-28 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | C型肝炎ウイルス複製系 |
AU2006295716B2 (en) * | 2005-09-30 | 2011-11-03 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Novel recombinant human hepatitis C virus-like particle and method for producing the same |
CN101321865B (zh) * | 2005-09-30 | 2011-12-14 | 日本国立感染症研究所 | 感染性丙型肝炎病毒颗粒高效生产体系 |
JP2009051733A (ja) * | 2005-12-13 | 2009-03-12 | Univ Kurume | C型肝炎ウイルス由来ペプチド |
JP2008161080A (ja) * | 2006-12-27 | 2008-07-17 | Japan Health Science Foundation | C型肝炎ウイルス阻害剤を検出するためのアッセイ方法 |
WO2008133468A1 (en) * | 2007-04-27 | 2008-11-06 | Postech Academy-Industry Foundation | An efficiently replicable heptitis c virus mutant, a heptitis c virus mutant comprising reporter gene a method of preparing of hcv vaccine using the same and a method of screening anti hcv composition using the same |
EP2186893A4 (de) | 2007-07-13 | 2010-10-20 | Jp Nat Inst Infectious Disease | Herstellung und verwendung eines mit einem epitop-tag versehenen hepatitis-c-viruspartikels |
US20100291545A1 (en) | 2007-07-25 | 2010-11-18 | Takaji Wakita | Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof |
JP5584407B2 (ja) * | 2008-03-07 | 2014-09-03 | 公益財団法人東京都医学総合研究所 | C型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス |
CA2722423A1 (en) * | 2008-04-22 | 2009-10-29 | Rutgers, The State University | Hcv e2 construct compositions and methods |
US9758794B2 (en) | 2008-04-22 | 2017-09-12 | Rutgers, The State University Of New Jersey | HCV E2 construct compositions and methods |
CA2722043A1 (en) | 2008-04-25 | 2009-10-29 | Toray Industries, Inc. | Nucleic acid comprising chimeric gene derived from hepatitis c virus |
US8834893B2 (en) | 2008-12-26 | 2014-09-16 | Toray Industries, Inc. | Nucleic acid derived from hepatitis C virus and expression vector, transformed cell, and hepatitis C virus particles each prepared by using the same |
US20120251572A1 (en) * | 2009-09-30 | 2012-10-04 | Takaji Wakita | Hepatitis c virus vaccine composition |
JP5756757B2 (ja) | 2009-10-30 | 2015-07-29 | 東レ株式会社 | C型肝炎ウイルス(hcv)に対して感染阻害活性を有する抗体及びその用途 |
CN102199613A (zh) | 2010-03-25 | 2011-09-28 | 国立大学法人东京大学 | 感染性丙型肝炎病毒高生产hcv突变体及其应用 |
WO2012133735A1 (ja) | 2011-03-31 | 2012-10-04 | 国立感染症研究所長が代表する日本国 | 遺伝子型1bのC型肝炎ウイルスゲノム由来の核酸を含む核酸構築物、及び該核酸構築物が導入されたC型肝炎ウイルスゲノム複製細胞、並びに感染性C型肝炎ウイルス粒子の製造方法 |
EP2716757A4 (de) | 2011-05-31 | 2015-02-25 | Jp Nat Inst Infectious Disease | Mutantes replikon aus dem genom des hepatitis-c-virus-stamms j6cf |
EP2752485A4 (de) | 2011-08-31 | 2015-06-24 | Japan As Represented By The Director General Of Nat Inst Of Infectious Diseases | Nukleinsäurekonstrukt mit einer aus einem genom des genotyps 3a-hcv gewonnenen nukleinsäure |
WO2013085889A1 (en) * | 2011-12-05 | 2013-06-13 | Duke University | Identification and cloning of transmitted hepatitic c virus (hcv) genomes by single genome amplification |
JP6283315B2 (ja) * | 2012-09-28 | 2018-02-21 | 国立大学法人神戸大学 | C型肝炎ウイルス粒子形成促進剤及びc型肝炎ウイルス粒子の産生方法 |
CN109609505A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院成都生物研究所 | 一种体内筛选的剪切rna的锤头状核酶 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428145A (en) | 1991-08-09 | 1995-06-27 | Immuno Japan, Inc. | Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems |
JPH06121689A (ja) | 1991-08-09 | 1994-05-06 | Tetsuo Nakamura | 非a非b型肝炎ウイルス遺伝子、ポリヌクレオチド、ポリペ プタイド、抗原、抗体検出系 |
DE19915178A1 (de) | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
EP1185665B1 (de) | 1999-06-04 | 2008-09-10 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Infektiöses cdna klon des gb-virus b und dessen verwendungen |
DE60034884T2 (de) | 1999-06-04 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen |
JP4880116B2 (ja) * | 2000-12-01 | 2012-02-22 | 財団法人 東京都医学総合研究所 | 劇症c型肝炎ウイルス株の遺伝子 |
US20030009775A1 (en) | 2001-05-25 | 2003-01-09 | Glenn Jeffrey S. | Mouse model for hepatitis C |
JP3811854B2 (ja) | 2002-05-10 | 2006-08-23 | 清水建設株式会社 | 制震機構 |
JP2004045489A (ja) | 2002-07-09 | 2004-02-12 | Fuji Photo Film Co Ltd | 感光性樹脂転写材料を用いた金属酸化物構造体の製造方法 |
JP2006506074A (ja) * | 2002-11-13 | 2006-02-23 | ワシントン ユニヴァーシティー | C型肝炎ウイルスの複製に対して高許容性である細胞系 |
WO2004104198A1 (ja) | 2003-05-26 | 2004-12-02 | Toray Industries, Inc. | 遺伝子型2aのC型肝炎ウイルス(HCV)ゲノム由来の核酸を含む核酸構築物、及び該核酸構築物を導入した細胞 |
CA2851807C (en) * | 2004-02-20 | 2016-06-28 | Toray Industries, Inc. | Nucleic acid construct containing full length genome of human hepatitis c virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis c virus particle |
-
2005
- 2005-02-21 CA CA2851807A patent/CA2851807C/en not_active Expired - Fee Related
- 2005-02-21 CN CN2005800115150A patent/CN1942585B/zh not_active Expired - Fee Related
- 2005-02-21 CA CA2558685A patent/CA2558685C/en not_active Expired - Fee Related
- 2005-02-21 US US10/589,902 patent/US7659103B2/en not_active Expired - Fee Related
- 2005-02-21 EP EP08007293A patent/EP1942191B1/de not_active Expired - Fee Related
- 2005-02-21 ES ES08007293T patent/ES2366303T3/es active Active
- 2005-02-21 KR KR1020067018856A patent/KR101154278B1/ko active IP Right Review Request
- 2005-02-21 EP EP05719575A patent/EP1721985B1/de not_active Expired - Fee Related
- 2005-02-21 WO PCT/JP2005/003232 patent/WO2005080575A1/ja active Application Filing
- 2005-02-21 CN CN201110066226.8A patent/CN102206663B/zh not_active Expired - Fee Related
- 2005-02-21 DE DE602005022052T patent/DE602005022052D1/de active Active
- 2005-02-21 ES ES05719575T patent/ES2346326T3/es active Active
- 2005-02-21 JP JP2006510335A patent/JP4921164B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-21 US US12/583,465 patent/US8460912B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20080220019A1 (en) | 2008-09-11 |
KR20070011310A (ko) | 2007-01-24 |
ES2366303T3 (es) | 2011-10-19 |
EP1721985A4 (de) | 2007-03-14 |
JPWO2005080575A1 (ja) | 2007-08-02 |
CN1942585B (zh) | 2011-05-11 |
CN102206663A (zh) | 2011-10-05 |
WO2005080575A1 (ja) | 2005-09-01 |
CN102206663B (zh) | 2014-02-05 |
KR101154278B1 (ko) | 2012-06-21 |
US7659103B2 (en) | 2010-02-09 |
EP1942191B1 (de) | 2011-06-22 |
CA2851807A1 (en) | 2005-09-01 |
CA2558685A1 (en) | 2005-09-01 |
US8460912B2 (en) | 2013-06-11 |
CN1942585A (zh) | 2007-04-04 |
EP1942191A1 (de) | 2008-07-09 |
US20100047896A1 (en) | 2010-02-25 |
CA2558685C (en) | 2014-08-12 |
EP1721985A1 (de) | 2006-11-15 |
ES2346326T3 (es) | 2010-10-14 |
JP4921164B2 (ja) | 2012-04-25 |
EP1721985B1 (de) | 2010-06-30 |
CA2851807C (en) | 2016-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005022052D1 (de) | Nukleinsäurekonstrukt mit vollängengenom des menschlichen hepatitis-c-virus, rekombinantes vollängen-virusgenom replizierende zelle mit dem in sie übertragenen nukleinsäurekonstrukt und verfahren zur konstruktion von hepatitis-c-viruspartikeln | |
DE60333042D1 (de) | Eine aus dem genom von hepatitis-c-virus (hcv) genotyp 2a stammende nukleinsäure enthaltendes nukleinsäurekonstrukt und zelle mit dem dahinein transferierten nukleinsäurekonstrukt | |
BRPI0612662A2 (pt) | composição antiviral e métodos de redução da atividade viral e de um vírus de rna de filamento simples e da resposta pró-inflamatória e/ou tempestade de citocina numa célula ou sujeito e de aumento dos níveis de glutationa em sujeito infectado viralmente | |
IL188202A0 (en) | Methods and compositions for expressing negative-sense viral rna in canine cells | |
DE602005002694D1 (de) | System und Methode um einen aussergewöhnlichen Kontrollfluss in geschütztem Kode durch Beobachtungspunkte zur Verfügung zu stellen | |
GB0514909D0 (en) | Methods of nucleic acid amplification and sequencing | |
DK1856295T3 (da) | Sammensætninger og fremgangsmåder til detektion af virale specifikke nukleinsyrer i urin | |
SG11202107922QA (en) | Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response | |
HRP20230259T1 (hr) | Mutant polipeptida faktora ix, njegove primjene i postupak za njegovu proizvodnju | |
DK2019872T3 (da) | Fremgangsmåde til forudsigelse af modtageligheden over for TNF-blokkere | |
HK1136849A1 (en) | Methods and compositions for expressing negative-sense viral rna in canine cells rna | |
WO2006038129A3 (en) | Hepatitis c virus replication system | |
ATE521695T1 (de) | Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapie | |
ATE552335T1 (de) | An das wachstum in suspension angepasste vero- zellinie, verfahren zur gewinnung davon und virale impfstoffe | |
Panigrahi et al. | MicroRNA-122 regulation of HCV infections: Insights from studies of miR-122-independent replication | |
EP1591524A4 (de) | Oligoribonukleotid oder peptidische nukleinsäure, das bzw. die die funktion des hepatitis-c-virus hemmt | |
WO2007001928A3 (en) | Targets for inhibiting hcv replication | |
GB2425534B (en) | Nucleic Acid Complex And Method Of Introducing Nucleic Acid into Cell Using The Same | |
DE602004010307D1 (de) | Verwendung von polysulfatiertem alginat in zellmatrix | |
WO2007095055A3 (en) | Methods and compositions for detecting viral nucleic acid in a cell | |
Bagheri-Mansoori et al. | The survey on-592 polymorphism of interlukin-10 in hepatitis b virus infected patients. | |
WO2008002400A3 (en) | Methods for altering cellular susceptibility to infection | |
ZA200711164B (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
Keshvari et al. | Can we include genetic variants with high linkage disequilibrium into a multiple logistic model? | |
Bhambri et al. | Gene expression program of regeneration in Eisenia fetida: a transcriptomics study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R082 | Change of representative |
Ref document number: 1721985 Country of ref document: EP Representative=s name: PRUEFER & PARTNER GBR, 81479 MUENCHEN, DE |